Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Study shows lack of physical activity in 42% of adults with RA

Study shows lack of physical activity in 42% of adults with RA

Amgen enters definitive merger agreement to acquire Micromet

Amgen enters definitive merger agreement to acquire Micromet

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

New book focuses on improving care for chronic diseases

New book focuses on improving care for chronic diseases

Testing for osteoporosis – how often?

Testing for osteoporosis – how often?

Patients with PsA may benefit from new medications and surgeries

Patients with PsA may benefit from new medications and surgeries

Researchers discover HS1.2 enhancer as the cause of SLE

Researchers discover HS1.2 enhancer as the cause of SLE

Scientists discover specific immune system T cells that trigger destruction of type 1 diabetes

Scientists discover specific immune system T cells that trigger destruction of type 1 diabetes

Researchers identify mechanism that makes retinoblastoma so aggressive

Researchers identify mechanism that makes retinoblastoma so aggressive

Cardinal Health launches infusion room management tool for community rheumatologists

Cardinal Health launches infusion room management tool for community rheumatologists

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

Synthetic drugs treat Crohn's disease in mice

Synthetic drugs treat Crohn's disease in mice

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

Lexicon completes rights offering

Lexicon completes rights offering

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.